Parnell announces 2019 year-to-date revenue growth of 9% over the first 9 months of 2018, start of work on its new 2019 CMO contract, and updates to 2019 financial results.

Parnell announces a new contract manufacturing agreement for one animal health product and a memorandum of understanding for two additional products with a global multi-national; revenue in the first half of 2019 down 12% compared to 2018 due to timing of technology transfer revenues versus prior year; and holds 2019 guidance for a 17 - 25% increase over 2018 revenue and an EBITDA range of $7.5 - $8.5m.

Parnell delivers 9% revenue growth in Quarter 1 of 2019 compared to 2018, and confirms provisional 2019 guidance for a 17 - 25% increase over 2018 revenue to $31 - $33 million and an EBITDA range of $7.5 - $8.5 million subject to winning at least one new Contract Manufacturing agreement in 2019.

Parnell delivers 39% revenue growth and a $6.5 million improvement in EBITDA in 2018 compared to 2017, returns to NPAT profitability, and provides provisional 2019 guidance for a 17 - 25% increase over 2018 revenue to $31 - $33 million and an EBITDA range of $7.5 - $8.5 million.